Ascelia Pharma Q2 2026 slides: FDA setback delays Orviglance path

Ascelia Pharma (STO:ACE) reported its Q2 2026 results on August 20, 2026, highlighting the impact of an FDA setback on its lead drug candidate, Orviglance. The Swedish biotech company discussed its regulatory strategy and cost reduction initiatives, but investor caution prevailed as shares traded near the lower end of its 52-week range.

The FDA's Complete Response Letter (CRL) raised concerns related to clinical and statistical issues, as well as product quality specifications. Ascelia responded to the FDA's concerns, asserting that systematic bias in lesion scoring required a re-read of images. The company reported an operating loss of SEK 12 million for Q2 2026, a significant improvement from the previous year.

Cash reserves increased to SEK 38 million, providing a runway into Q2 2027. Despite the regulatory uncertainty, Ascelia emphasized the commercial value of Orviglance, a first-in-class contrast agent for liver MRI in patients with impaired kidney function. The company's commercialization strategy relies on partnering with potential commercial partners.